Treatment of Tuberculosis in a Region with High Drug Resistance
Author Information
Author(s): Maryline Bonnet, Manuela Pardini, Francesca Meacci, Germano Orrù, Hasan Yesilkaya, Thierry Jarosz, Peter W. Andrew, Mike Barer, Francesco Checchi, Heinz Rinder, Graziella Orefici, Sabine Rüsch-Gerdes, Lanfranco Fattorini, Marco Rinaldo Oggioni, Juliet Melzer, Stefan Niemann, Francis Varaine
Primary Institution: Clinical Research department, Epicentre, Geneva, Switzerland
Hypothesis
How does drug resistance affect tuberculosis treatment outcomes in Abkhazia?
Conclusion
In Abkhazia, individualized MDR-TB treatment regimens resulted in poor treatment outcomes and XDR-TB amplification.
Supporting Evidence
- 85.2% treatment success was observed in fully drug-susceptible patients.
- Only 32.3% of MDR-TB patients achieved treatment success.
- 3 patients with fully susceptible strains were re-infected with MDR-TB during treatment.
Takeaway
This study looked at how well tuberculosis treatments work in a place where many people have drug-resistant TB. It found that the treatments didn't work very well for those with the most severe drug resistance.
Methodology
The study combined drug susceptibility results and molecular strain typing data with treatment outcome reports in a prospective cohort of patients.
Potential Biases
Potential bias due to the chronic conflict situation affecting TB control and treatment adherence.
Limitations
The study was limited by the small sample size of MDR-TB patients and the lack of HIV testing.
Participant Demographics
The cohort included 326 patients, predominantly male (252 males, 74 females), with a mean age of 42 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website